Toxicity of Combinations of Kinase Pathway Inhibitors to Normal Human Cells in a Three-Dimensional Culture

The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis

(2020) Maged. W. Helmy et al.   MOLECULAR BIOLOGY REPORTS

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds

(2020) Denis L. Jardim et al.   OncoImmunology

Organotypic breast tumor model elucidates dynamic remodeling of tumor microenvironment

(2020) Sunil Singh et al.   BIOMATERIALS

Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours

(2020) Fei Xu et al.   Cell and Bioscience

Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids

(2020) Brooke Schuster et al.   Nature Communications

Trends in clinical success rates and therapeutic focus

(2019) Helen Dowden et al.   NATURE REVIEWS DRUG DISCOVERY

A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip

(2019) Sasan Jalili-Firoozinezhad et al.   Nature Biomedical Engineering

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

(2019) Rebecca C. Arend et al.   GYNECOLOGIC ONCOLOGY

Essential nucleotide- and protein-dependent functions ofActb/β-actin

(2018) Xiaobai Patrinostro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors

(2018) Pradip Shahi Thakuri et al.   Translational Oncology

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

(2017) Zev A. Wainberg et al.   Targeted Oncology

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

(2017) Trisha M. Wise-Draper et al.   Targeted Oncology

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

(2017) Dominika E. Butler et al.   Oncotarget

Three-dimensional tumor model mimics stromal – breast cancer cells signaling

(2017) Stephanie Lemmo Ham et al.   Oncotarget

Characterization of Aqueous Two-Phase Systems from Volume and Density Measurements

(2016) Ehsan Atefi et al.   JOURNAL OF CHEMICAL AND ENGINEERING DATA

Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids

(2016) Pradip Shahi Thakuri et al.   MOLECULAR PHARMACEUTICS

Combine and conquer: challenges for targeted therapy combinations in early phase trials

(2016) Juanita S. Lopez et al.   Nature Reviews Clinical Oncology

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

(2016) Maria I. Carlo et al.   ONCOLOGIST

Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors

(2016) Stephanie L. Ham et al.   Advanced Healthcare Materials

Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results

(2016) Thomas J. Hwang et al.   JAMA Internal Medicine

The Flaws and Human Harms of Animal Experimentation

(2015) AYSHA AKHTAR   CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS

High Throughput, Polymeric Aqueous Two-Phase Printing of Tumor Spheroids

(2014) Ehsan Atefi et al.   ADVANCED FUNCTIONAL MATERIALS

PI3K/AKT signaling pathway and cancer: an updated review

(2014) Miriam Martini et al.   ANNALS OF MEDICINE

Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-cancer Drug Testing in 3D Culture

(2014) Stephanie Lemmo et al.   Cellular and Molecular Bioengineering

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

(2013) Carolyn D. Britten   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

(2013) Kamal S. Saini et al.   CANCER TREATMENT REVIEWS

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

(2013) J. Renshaw et al.   CLINICAL CANCER RESEARCH

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

(2012) T. M. Williams et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

The diverse functions of GAPDH: Views from different subcellular compartments

(2010) Carlos Tristan et al.   CELLULAR SIGNALLING

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE